WO2008023947A1

WO2008023947A1 - A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma

Info

Publication number: WO2008023947A1
Application number: PCT/KR2007/004046
Authority: WO
Inventors: Hyo Jeong Hong; Jung-Whoi Lee; Jin Man Kim; Yeon Sung Son; Eung Suck Lee
Original assignee: Korea Research Institute Of Bioscience And Biotechnology
Priority date: 2006-08-23
Filing date: 2007-08-23
Publication date: 2008-02-28
Also published as: WO2008023946A1; EP2054083A4; CN101528258A; JP2010501549A; JP2015007045A; BRPI0715845A2; KR100931976B1; EP2054083B1; KR20080018149A; CA2661669C; AU2007288620B2; CN101605560A; CA2661669A1; KR20080018150A; KR100932698B1; EP2054083A1; AU2007288620A1; MX2009002064A; BRPI0715844A2; US20100196350A1

Abstract

Disclosed herein are a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoiria, comprising a LlCAM activity inhibitor or expression suppressor and a treatment method using the composition. This is based on the finding that LlCAM is overexpressed on cholangiocarcinoma and plays an important role in the growth and metastasis of cholangiocarcinoma and the mortality of cholangiocarcinoma patients increases as the expression rate of LlCAM increases. Also, antibodies inhibitory of the activity of LlCAM, or siRNAs suppressing the expression of LlCAM, are found to reduce the growth and invasion of cholangiocarcinoma cells. Mouse monoclonal antibodies, recognizing the LlCAM protein on the cholangiocarcinoma cell surface and binding specifically to cholangiocarcinoma tissues, or siRNAs, antisense oligonucleotides or shRNAs, may be useful in the treatment of cholangiocarcinoma by inhibiting the growth, invasion and migration of cholangiocarcinoma cell.

Description

[DESCRIPTION]

[Invention Title]

A PHARMACEUTICAL, COMPOSITION FOR TREATING CHOLANGIOCARCINOMA, A METHOD FOR INHIBITING GROWTH OR INVASION OF CHOLANGIOCARCINOMA AND A METHOD FOR TREATING CHOLANGNIOCARCINOMA

[Technical Field]

<i> The present invention relates to a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoma, comprising a substance inhibiting the activity or expression of LlCAM, which is a protein present on the surface of cholangiocarcinoma cells, and to a treatment method using the composition.

<2>

[Background Art]

<3> Cholangiocarcinoma is a cancer of the bile ducts, which drain bile from the liver into the small intestine. Recent evidence has suggested that the liver cancer may arise from a pluripotent hepatic stem cell (Sell and Dunsford Am J. Pathol. 134:1347-1363, 1989). Cholangiocarcinoma entails far lower morbidity worldwide than does liver cancer, with a far higher occurrence in South East Asia than in Europe or North America. Cholangiocarcinoma is not effectively treated by surgical removal because of its high return rate. General chemotherapy and radiotherapy are not useful for the treatment of cholangiocarcinoma (Pederson et al Cancer Res. 4325- 4332, 1997) either. In addition, cholangiocarcinoma is difficult to diagnose, and it has been observed that the chronic inflammation, attributed to the infection of bacteria or parasites into the bile ducts, is predisposed to develop into cholangiocarcinoma (Roberts et al . , Gastroenterology 112:269- 279, 1997).

<4> In spite of the large amount of research results, the pathogenesis of cholangiocarcinoma still remains unknown. Target molecules for the treatment of cholangiocarcinoma are also poorly understood. Only a few cell lines have been established, as a result of some cytogenetic study (Yamaguchi et al., J. Nat ¹I Cancer Inst 75: 29-35, 1985; Ding et al., Br J Cancer 67: 1007-1010, 1993). However, there has been no report of methods for preparing an antibody specific for cholangiocarcinoma using these cell lines.

<5> Recently, cholangiocarcinoma cell lines Choi-CK and SCK were established from Korean patients suffering from cholangiocarcinoma (Kim et al, Genes, chromosome & Cancer 30:48-56, 2001). If monoclonal antibodies specific to the cell surface are prepared from the mice injected with the cholangiocarcinoma cell line, they can be applied to the treatment of cho1angiocarcinoma.

<6> The gene of epidermal growth factor receptor (EGFR), known as a prognostic factor, is a proto-oncogene. EGFR is involved in tumorigenesis and aggressive growth behaviour. EGFR is overexpressed in various cancers, including breast cancer, lung cancer, colorectal cancer, kidney cancer, gall bladder carcinoma, head and neck cancer, ovarian cancer, prostate cancer, cancerous cervical tumors, and stomach cancer (Modjtahedi, H. and Dean, C, The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int. J. Oncol. 4: 277-296, 1994). In addition, the association of EGFR expression with cancer prognosis differs from one cancer to another (Nicholson, R.I. et al . EGFR and cancer prognosis. Eur. J. Cancer 37, S9-S15, 2001). For example, EGFR can be used as a strong prognosis factor for bladder cancer, cancerous cervical tumors, esophageal cancer, head and neck cancer, and ovarian cancer, but is recognized as a weak prognostic indicator for non-small cell lung carcinoma (NSCLC). However, there is no information known about prognostic factors for cholangiocarcinoma.

<7> When antibodies against EGFR are applied to the treatment of cancers, their inhibitory activity against cancer cell growth was found to vary in efficiency by 15-50 % for each cancer type. Also, there is a difference between in vitro and in vivo growth inhibition effects even in the same cancer type (Dassonville, 0. et al., EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences. Critical Reviews in Oncology/Hematology 62, 53-61, 2007). Currently, antibodies against EGFR are used as therapeutics for colorectal cancer and head and neck cancer, but are not applied to the treatment of all of the above-exemplified cancerous diseases, in which EGFR is overexpressed. <8> As explained above, expression in cancer cells does not simply guarantee protein to be a prognostic factor for the cancer. Also, whether or not the expression of a protein in cancer cells is associated with cancer prognosis depends on the type of cancer. A strong and poor prognostic factor for cancer can be utilized not only to readily predict the effects of treatment and prognosis of a therapeutic on the cancer, but also to develop a prognostic factor-targeting therapeutic which can be applied selectively and effectively to the cancer of interest. Thus, the discovery of such prognostic factors specific for cancers is very important in the diagnosis and treatment of cancers.

<9>

<io> Ll cell adhesion molecule (LlCAM), an integral membrane glycoprotein of 220 kDa, is a member of the immunoglobulin superfamily of cell adhesion molecules (CAMs), which mediate cell-to-cell adhesion on the cell surface. LlCAM, originally identified in neurons (Bateman, et al , EMBO J. 15:6050- 6059; 1996), plays a critical role in neural migration, neurite outgrowth and cell migration. The human LlCAM gene was isolated from an embryonic human brain cDNA library using degenerate oligonucleotides derived from LlCAM homologues of mice and rats as probes (Hlavin, M. L. & Lemmon, V. Genomics 11: 416-423, 1991; U. S. Pat. No. 5,872,225, issued on Feb. 16, 1999). LlCAM is expressed primarily in the brain, and its expression is also detected in some normal tissue, and has recently been detected in several types of cancer .

<11>

<i2> There seems to be an association between LlCAM and cancer. LlCAM has been reported to be expressed in many tumor cell types, including melanoma, neuroblastoma, ovarian carcinoma and colorectal carcinoma (Takeda, et al., J. Neurochem. 66:2338-2349, 1996; Thies et al., Eur. J. Cancer, 38:1708-1716, 2002; ArIt et al . , Cancer Res. 66:936-943, 2006; Gavert et al . , J. Cell Biol. 168:633-642, 2005). LlCAM has been found not only in the membrane-bound form but also as a cleavage product, which is secreted to the extracellular matrix (Gutwein et al., FASEP J. 17(2):292-4, 2003). Recently, LlCAM has been shown to be a molecule that plays an important role in the growth of tumor cells (Primiano, et al . , Cancer Cell. 4(1):41-53 2003) and is arising as a new target for cancer therapy (US2004/0115206 Al, filed on June 17, 2004). Recent studies also showed that LlCAM is expressed at the invasive front of human colon cancer tissue (Gavert, et al., J Cell Biol. 14; 168(4) :633-42. 2005) and anti-LICAM antibodies function to inhibit the growth and metastasis of ovarian cancer cells (ArIt, et al., Cancer Res. 66:936-943. 2006). <13> Nowhere is the expression of LlCAM in cholangiocarcinoma cells mentioned in previous reports. Further, there has not yet been any information about whether LlCAM is involved in the growth and metastasis of cholangiocarcinoma. Also, data about whether cholangiocarcinoma patients show higher mortality when LlCAM is expressed at a higher level in the cancer cells, that is, whether LlCAM is a poor prognostic factor for cholangiocarcinoma, have not been published at all. Thus, it was not known prior to the present invention that an antibody against LlCAM has potential as a therapeutic drug by inhibiting the proliferation and metastasis of cholangiocarcinoma, as well.

<14>

<15> EP 1,172,654 Al and U. S. Pat. Publication No. 2004/0259084 disclose a method for the diagnosis and prognosis of an ovarian or endometrial tumors, characterized in that the LlCAM level is determined in a patient sample on the basis that the presence of LlCAM is an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor, and a method of treating ovarian or endometrial tumors in a patient in need of such treatment, comprising administering to the patient a sufficient amount of a LlCAM antibody or a fragment thereof conjugated to a cytotoxic drug. As disclosed in these patents, the LlCAM protein is described only as a marker specific for ovarian or endometrial tumors.

<16>

<17> U. S. Pat. Publication No. 2004/0115206 discloses a method and a reagent for inducing cell death in tumor cells using an antibody specifically binding to LlCAM, and pharmaceutical compositions comprising the LlCAM antibody. The method is featured by contacting the tumor cell with an effective amount of an anti-LICAM antibody for a time and at a concentration sufficient so as to inhibit cell growth or induce cell death in the tumor cell. Mentioning breast cancer, colon cancer and cervical carcinoma cells as examples of LlCAM-expressing tumor cells, this patent publication provides only in-vitro test results, but is not supported by in-vivo data. Nowhere is a relationship between LlCAM and cholangiocarcinoma elucidated therein. Further, this patent publication indicates only that the tumor cell contacts the anti-LICAM antibody in order to inhibit cell growth and induce cell death, without any suggestion that the anti-LICAM antibody is able to inhibit the migration, invasion and metastasis of tumor cells.

<18> International Patent Application No. PCT/EP2005/008148 discloses a LICAM protein overexpressed in ovarian and endometrial carcinoma, a pharmaceutical composition for interfering with the expression of LlCAM, and a method for the prevention and treatment of ovarian and endometrial carcinoma using the composition. The pharmaceutical composition, comprising an anti-LICAM antibody or a derivative thereof, is described as being able to treat ovarian and endometrial carcinoma by inhibiting the migration and growth of the cancer cells. This patent application also mentions only ovarian and endometrial carcinoma in which LICAM in a cell-bound form or a soluble form functions to promote the migration of cancer cells.

<19> In brief, none of the literature prior to the present invention discloses that LlCAM is expressed at high levels in cholangiocarcinoma and can thus be used as a poor prognostic factor specific for cholangiocarcinoma, and that a LlCAM inhibitor, such as an antibody to LlCAM, can accordingly be useful in the diagnosis and treatment of cholangiocarcinoma.

<20>

[Disclosure] [Technical Problem]

<2i> The present inventors conducted intensive and thorough research into the development of antibodies useful in cancer diagnosis and treatment. Mice were immunized with the recently established cholangiocarcinoma cell line (Kim et al., Genes, Chromosomes & Cancer 30:48-56, 2001), thereby obtaining a monoclonal antibody binding specifically to LlCAM on the cholangiocarcinoma cell surface. The obtained monoclonal antibody was designated "A10-A3," and this antibody was found to specifically recognize LlCAM.

<22> Also, LlCAM was found to be expressed on the surface of cholangiocarcinoma cells, but not on the surface of normal cells, such as peripheral lymphocytes, hepatocytes, vascular endothelial cells, etc., as assayed with the A10-A3 antibody and known anti-LlCAM antibodies. LlCAM has been known to be expressed in breast cancer, ovarian cancer, colorectal cancer, skin cancer, etc., but remained unknown about expression on cholangiocarcinoma. Experiments with A10-A3 antibody, conducted by the present inventors, showed that LlCAM was overexpressed in 45.2% of 42 intrahepatic cholangiocarcinoma patients and 39.8% of 103 extrahepatic cholangiocarcinoma patients, particularly in the invasive front, which accounts for the metastasis initiation of cholangiocarcinoma. Also, statistical analysis of the correlation between LlCAM expression rate and survival rate showed that the mortality of cholangiocarcinoma patients with a high LlCAM expression rate was far higher than that of the cholangiocarcinoma patients with a low LlCAM expression rate. Demonstrating that LlCAM is a poor prognostic factor for cholangiocarcinoma, this result indicates that LlCAM can be an important target for the treatment of cholangiocarcinoma.

<23>

<24> Although expressed at a high level in cholangiocarcinoma, in contrast, EGFR, which is used as a target of therapeutic agents for current clinical use in the treatment of colon cancer (e.g., cetuximab, a chimeric antibody to EGFR), was proven not to be a poor prognostic factor for cholangiocarcinoma because no statistical significance was found in the analysis of a correlation between EGFR expression rates and survival rates. Thus, EFGR is recognized not to be a poor prognostic factor for cholangiocarcinoma. Thus, not all of the molecules overexpressed in cancer can be used as important targets for the treatment thereof.

<25>

<26> When LlCAM expression was suppressed by introducing siRNA against LlCAM into LlCAM-expressing cholangiocarcinoma cell lines (Choi-CK, SCK), the growth, migration and invasion thereof was found to be suppressed. These results indicate that LlCAM plays an important role in the growth and metastasis of cholangiocarcinoma.

<27> Antibodies to LlCAM were found to have inhibitory activity against the growth, migration or invasion of cholangiocarcinoma cells, as assayed by treating cholangiocarcinoma cell lines (Choi-CK, SCK) with A10-A3 antibody or a known anti-LICAM antibody (UJ127). In addition, the injection of A10-A3 antibody inhibited the growth of cholangiocarcinoma cells in nude mice which were transplanted with a cholangiocarcinoma cell line. Further, the monoclonal antibody 4-63, produced by a hybridoma (KCTC 10966BP) obtained from mice immunized with human embryonic stem cells, recognized LlCAM on the cancer cell surface, and inhibited the growth of cholangiocarcinoma. Leading to the present invention, thus, thorough and intensive research, conducted by the present inventors, has led to the conclusion that anti-LICAM antibodies are useful in the diagnosis and treatment of cholangiocarcinoma.

<28>

[Technical Solution]

<29> It is therefore an object of the present invention to provide a pharmaceutical composition for inhibiting the growth and metastasis of cholangiocarcinoma, comprising a substance inhibiting the activity of LlCAM or suppressing the expression of LlCAM. <30> It is another object of the present invention to provide a method of treating cholangiocarcinoma based on the use of the pharmaceutical composition. <3i> It is a further object of the present invention to provide an anti-

LlCAM antibody to inhibit the activity of LlCAM. <32> It is yet another object of the present invention to provide an oligonucleotide to inhibit the expression of LlCAM. <33> It is still another object of the present invention to provide a method of inhibiting the proliferation or metastasis of cholangiocarcinoma cells based on the use of the pharmaceutical composition.

[Description of Drawings]

<35> FIG. 1 shows the results of fluorescent cell staining and flow cytometry for the binding capacity of mouse monoclonal antibodies, A10-A3 (A) and 4-63 (B), and known antibodies 5G3 (C) and UJ127 (D) to the cell surface of various carcinoma cell lines including cholangiocarcinoma, and normal cells.

<36> FIG. 2 shows the results of immunoprecipitation and Western blotting, indicating that A10-A3 specifically binds to LlCAM. A: The cell surface of Choi-CK cholangiocarcinoma was biotinylated, and immunoprecipitation was carried out with the A10-A3 antibody or a known anti-LlCAM monoclonal antibody (UJ127). Precipitated proteins were subjected to 10% SDS-PAGE and Western blotting with Streptavidin-HRP. LlCAM was detected by Western blotting. B: Proteins were immunoprecipitated with A10-A3 antibody, separated on 10% SDS-PAGE and subjected to Western blotting using the known anti-LICAM antibody (UJ127). LlCAM was detected by Western blotting. "Preelearing," as a negative control, indicates immunoprecipitation (IP) in the absence of the antibody, "IP with A10-A3" indicates IP using A10-A3 antibody, "IP with anti-LICAM" indicates IP using a known anti-LICAM monoclonal antibody, and "A10-A3 only" indicates SDS-PAGE of the antibody only. C: Soluble Ll-expressing HEK293T cells were subjected to Western blotting using known antibodies, UJ127 and 5G3, and A10-A3 and 4-63 antibodies. "-" indicates a culture supernatant of cells not carrying Ll expression vector, and "+" indicates a culture supernatant of cells containing a soluble Ll expression vector.

<37> FIG. 3 shows the results of Q-TOF analysis. Proteins from Choi-CK cells were immunoprecipitated with an A10-A3 antibody, separated on SDS-PAGE, and trypsin-digested. The obtained peptides were analyzed using Q-TOF, which revealed that the immunoprecipitated protein is LlCAM. The lower amino acid sequence represents the full-length LlCAM, and upper amino acid sequences show the sequences of the analyzed peptides, corresponding to the underlined parts of the full-length LlCAM sequence. <38> FIG. 4 shows the results of the immunohistocheraical staining of carcinoma tissues from cancer patients using A10-A3 (A and C) and 4-63 (B) antibodies. The antibodies were found to bind to human cholangiocarcinoma tissues but not to bind to normal hepatic tissues.

<39> FIG. 5 provides tables in which correlations between LlCAM expression in intrahepatic cholangiocarcinoma (A) and extrahepatic cholangiocarcinoma (B) and clinicopathological properties are summarized.

<40> FIG. 6 provides graphs showing correlations between LlCAM expression rate and survival rates of extrahepatic cholangiocarcinoma patients (60 cases) expressed as both OS (overall survival) and DFS (disease free survival).

<4i> FIG. 7 shows LlCAM expression levels in cholangiocarcinoma cells transfected with siRNA against LlCAM and non-specific siRNA (A) and the degrees of proliferation, invasion and migration of the transfected cells (B).

<42> FIG. 8 shows the inhibitory effects of anti-LlCAM antibodies A10-A3 (A), 4-63 (B) and UJ127 and 5G3 (C) on the growth of the cholangiocarcinoma cell line Choi-CK and SCK. The ovarian cancer cell line SK-0V3 and the renal cancer cell line ACHN, to which the A10-A3 antibody did not bind, were used as a positive cell control and a negative cell control, respectively. For a negative antibody control, treatment with no antibody (control), a heat- inactivated antibody (boiled A10-A3b or 4-63b) or normal mouse IgG was conducted. The degree of cell growth was expressed as a percentage relative to a control not containing any antibody after the cells were incubated for 72 hours with 10 βg/val of antibody.

<43> FIG. 9 shows the inhibitory effects of the anti-LlCAM antibodies AlO- A3, 4-63 and 5G3 on the invasion and migration of cholangiocarcinoma cells (Choi-CK, SCK). The renal cancer cell line ACHN, to which the A10-A3 antibody did not bind, was used as a negative cell control while, for a negative antibody control, treatment with no antibody (control), a heat- inactivated antibody (boiled A10-A3b or 4-63b) or normal mouse IgG was conducted. The degree of cell growth was expressed as a percentage relative to a control not containing any antibody after the cells were incubated for 72 hours with 10 μg/ml of antibody.

<44> FIG. 10 shows that the A10-A3 antibody inhibits signal transduction involved in the growth, migration and survival of cancer cells. The cholangiocarcinoma cell line Choi-CK or SCK was treated with A10-A3 antibody or mouse IgG, or was not treated with any antibody, and was then collected. Cell lysates were subjected to Western blotting using antibodies against PCNA (A), phospho-MAPK (A), phospho-AKT (B) and phospho-FAK (C). An anti-β-actin antibody was used to detect β-actin as a loading control.

<45> FIG. 11 shows the inhibitory effect of A10-A3 antibody on cancer growth in human cholangiocarcinoma xenograft mouse models. Panel A shows changes in tumor volume over time in 5 mice administered with the antibody (A10-A3 group) and 5 mice not administered with an antibody (control). Panel HB shows weights of tumors three weeks after the transplantation of cancer cells. Panel C shows the cancer tissues in photographs. Panel D is a graph in which the body weights of the mice were monitored for a period of time.

<46>

[Best Mode]

<47> In one aspect, the present invention is directed to a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoma, comprising a substance inhibiting the activity of LlCAM or suppressing the expression of LlCAM.

<48> In one embodiment thereof, the present invention provides a pharmaceutical composition comprising a substance inhibiting the activity of LlCAM. Preferably, the activity-inhibiting substance is an antibody that specifically recognizes a cholangiocarcinoma cell surface antigen or a secreted surface antigen (LlCAM). The antibody includes all monoclonal antibodies and chimeric antibodies, humanized antibodies and human antibodies thereof. Novel antibodies, as well as antibodies known in the art, fall within the scope of the present invention. Preferable is a novel anti-LlCAM monoclonal antibody A10-A3 or 4-63, a known anti-LICAM monoclonal antibody UJ127, or a chimeric, humanized or human antibody thereof. The A10-A3 and A- 63 antibodies are secreted by hybridomas having KCTC accession numbers KCTC 10909BP and KCTC 10966BP, respectively.

<49> As long as they have the binding specificity for LlCAM, the antibodies include complete forms having two full-length light chains and two full- length heavy chains, or may be in the form of functional fragments of antibody molecules. As used herein, the term "functional fragments of antibody molecules"is intended to refer to fragments retaining at least an antigen-binding function, which are exemplified by Fab, F(ab), F(ab')₂and Fv.

<50> In another embodiment of this aspect, according to the present invention, the pharmaceutical composition may include a substance suppressing the expression of LlCAM. When its expression level in LlCAM-expressing tumor cells is suppressed by an LlCAM expression inhibitor, the growth and metastasis of tumor cells decrease, which can be therefore applied to the treatment of such cancers. Preferably, the LlCAM expression inhibitor is selected from the group consisting of siRNAs, shRNAs and antisense oligonucleotides, and is preferably an siRNA containing a sequence of 5'- TGGTACAGTCTGGGdtdt-3' or 5'-CAGCAACTTTGCTCAGAGGdtdt-3' .

<5i> As used herein, the term "siRNA" is intended to refer to a small nucleic acid molecule of about 20 nucleotides, which mediates RNA interference or gene silencing. The term "shRNA" refers to a short hairpin RNA in which sense and antisense sequences of a siRNA target sequence are separated by a loop structure of 5 to 9 bases. Recently, the phenomenon of RNA interference (RNAi) has been studied for application to a method for controlling protein expression at the gene level. Typically, siRNA has been shown to inhibit protein expression by binding specifically to mRNA, having a sequence complementary to a target gene.

<52> siRNA, which is contained in the composition according to the present invention, can be prepared by direct chemical synthesis (Sui G et . al , (2002) Proc Natl Acad Sci USA 99:5515-5520) or in vitro transcription (Brummelkamp TR et al., (2002) Science 296:550-553), but the present invention is not limited to these methods. Also, shRNAs that are designed to overcome the drawbacks of siRNAs, including expensive siRNA biosynthesis and low transfection efficiency, leading to the short-term persistence of the RNA interference effect, can be expressed from an RNA polymerase Ill-based promoter contained in an adenoviral, lentiviral or plasmid expression vector system, which has been introduced into cells. The shRNA molecules are processed into functionalsiRNA molecules using an siRNA processing enzyme (Dicer or RNase III) within the cells, and then induce the silencing of a target gene.

<53> As used herein, the term "antisense" is intended to refer to an oligomer having a sequence of nucleotide bases and a subunit-to-subunit backbone that allows the antisense oligomer to hybridize with a target sequence in RNA by Watson-Crick base pairing to form an RNA:oligomer heteroduplex within the target sequence, typically with mRNA. The oligomer may have exact sequence complementarity to the target sequence, or near complementarity thereto. These antisense oligomers may block or inhibit the translation of the mRNA, and/or modify the processing of mRNA to produce a splice variant of the mRNA. Thus, the antisense oligomer of the present invention is an antisense oligomer complementary to the mRNA of the LlCAM gene.

<54> Preferably, the composition according to the present invention may include a known therapeutic agent, which is directly or indirectly conjugated to the antibody or is present in a non-conjugated form. The therapeutic agent capable of binding to the antibody includes, but is not limited to, radionuclides, drugs, lymphokines, toxins and bispecific antibodies. As long as it can exert therapeutic effects on cancer when conjugated to an antibody or administered in combination with a siRNA, a shRNA or an antisense oligonucleotide, any known therapeutic agent can be used in the present invention.

3 14

<55> Examples of the radionuclides include, but are not limited to, H, C, 1

³²n P, ³⁵SC, ³⁶πCl, ⁵VCr, ⁵VCo, ⁵VCo, ⁵⁹ϋFe, ⁹⁰VY, ¹²⁵TI, ¹³¹TI, and A ¹⁸⁶DRe.

<56> The drugs and toxins useful in the present invention include etoposide, teniposide, adriamycin, daunomycin, carminomycin, aminopterin, dactinomycin, mitomycin, cis-platinum and cis-platinum analogues, bleomycins, esperamicins, 5-fluorouracil , melphalan, and nitrogen mustard, but are not limited thereto.

<57> Preferably, the composition according to the present invention may include an acceptable carrier appropriate to the administration mode thereof.

<58> Formulations suitable for administration modes are known in the art. Also, the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount for cancer treatment. The typical dosage may be optimized using a standard clinical technique.

<59> In accordance with another aspect thereof, the present invention is directed to a method of treating cholangiocarcinoma based on the use of the pharmaceutical composition.

<60> In greater detail, the method comprises administering a pharmaceutically effective amount of the pharmaceutical composition to the body. The pharmaceutical composition may be administered parenteral Iy, subcutaneousIy, intrapulmonarily or intranasal Iy. For local immunosuppressive therapy, the composition may, if desired, be administered using a suitable method, including intralesional administration. Parenteral injections include intramuscular, intravenous, intraarterial, intraperitoneal and subcutaneous routes. Preferred administration modes include intravenous, subcutaneous, intradermal, intramuscular and drip injections.

<6i> Cholangiocarcinomamay be treated by administering the pharmaceutical composition of the present invention to the body, wherein an LlCAM-specific antibody, contained in the composition, binds to the cancer cell surface antigen LlCAM, thereby inhibiting the proliferation or metastasis of cholangiocarcinoma cells.

<62> Also, cholangiocarcinoma may be treated by administering the pharmaceutical composition of the present invention to the body to allow the antibody to bind to secreted LlCAM, which induces the blockage of the growth and metastasis of cancer cells. Alternatively, the antibody, when injected, binds to the cancer cell surface antigen LlCAM, so that immune cells recognize this association, leading to the phagocytosis, apoptosis or killing of the cancer cells.

<63> Cholangiocarcinoma treatment may also be achieved by inhibiting the expression of LlCAM using the LlCAM expression inhibitor contained in the pharmaceutical composition of the present invention. In this case, the stimulatory action of LlCAM on the growth and metastasis of cholangiocarcinoma cells decreases.

<64> In accordance with a further aspect thereof, the present invention is directed to an antibody against LlCAM for inhibiting the activity of LlCAM or an oligonucleotide against LlCAM for inhibiting the expression of LlCAM.

<65> In one embodiment of this aspect, as described for the composition according to the present invention, the antibody, as long as it binds specifically to LlCAM, includes complete forms having two full-length light chains and two full-length heavy chains, as well as functional fragments of antibody molecules. The functional fragments of antibody molecules are fragments that retain at least an antigen-binding function, and include Fab, F(ab), F(ab')₂and Fv.

<66> Preferably, the antibody recognizes the cholangiocarcinoma cell surface antigen or secreted surface antigen (LlCAM). The antibody is characterized in that it binds to the cholangiocarcinornacell surface protein LlCAM to inhibit or neutralize the action of LlCAM, and that, through binding to cancer cells, it inhibits the growth and metastasis of the cells, phagocytosizes the cells, induces apoptosis within the cells, or kills the cells.

<67> As described in Application US20040115206, anti-LICAM antibodies do not always inhibit the action of LlCAM. The present antibody is characterized in that it does not stimulate the action of LlCAM but inhibits the activity of LlCAM.

<68> More preferably, the antibody is a novel monoclonal antibody, A10-A3 or 4-63.

<69> In another embodiment, the present oligonucleotide against LlCAM, functioning to suppress the expression of LlCAM, is selected from among siRNAs, shRNAs and antisense oligonucleotides against LlCAM, which are specified for the present composition.

<70> In a further embodiment, cholangiocarcinoma cells were cultured on a large scale and injected into the foot pads of mice. Lymphocytes were extracted from the lymph nodes of mice and fused with myeloma tumor cells to yield mouse hybridomas producing antibodies binding to cholangiocarcinoma cells.

<7i> In detail, cholangiocarcinoma cell lines SCK and Choi-CK were injected into the foot pads of mice, and lymphocytes were extracted from the lymph nodes of mice. The isolated lymphocytes were fused with FO myeloma cells, and clones expressing antibodies were selected. Among the selected clones, supernatants of hybridomas that secreted monoclonal antibodies relatively stably were tested for binding capacity to cholangiocarcinoma cells. A monoclonal antibody-secreting hybridoma thus established was designated "hybridoma A10-A3". The hybridoma was deposited with an international depositary authority, KCTC (Korean Collection for Type Cultures; Korean Research Institute of Bioscience and Biotechnology (KRIBB), Korea) on Feb. 20, 2006, and assigned accession number KCTC10909BP.

<72>

<73> Separately, another antibody recognizing LlCAM, 4-63, was obtained using human embryonic stem cells, and was found to bind to cholangiocarcinoma and lung carcinoma cells. A hybridoma secreting the 4-63 antibody was deposited at KCTC and assigned accession number KCTC10966BP. In detail, the monoclonal antibodies were found to bind to carcinoma cell lines, such as cholangiocarcinoma (see, FIG. 1), but not to bind to normal cells, including hepatocytes, HUVEC (human umbilical vein endothelial cells) or peripheral blood lymphocytes (see, FIG. 1). The antibodies inhibited the growth, migration or invasion of cholangiocarcinoma. Also, a known anti-LICAM antibody 5G3 was observed to bind to cholangiocarcinoma cells, but to inhibit cancer growth only at a low efficiency (see, FIG. 8), while another known anti-LICAM antibody UJ127 was found to bind to cholangiocarcinoma cells and thus to inhibit the growth of the cells. These results indicate that anti- LICAM antibodies do not always inhibit the action of LlCAM.

<74>

<75> In another embodiment of the present invention, the expression level of LlCAM was found to be lower in Choi-CK and SCK cell lines transfected respectively with siRNA sequences of 5-TGGTACAGTCTGGGdtdt-3 and 5- CAGCAACTTTGCTCAGAGGdtdt-3 than in the same cell lines transfected with nonspecific oligonucleotides. Also, it was observed that a cancer cell group with siRNA knock-down of LlCAM was decreased in proliferation, invasion and migration compared to a cancer cell group that expressed LlCAM normally.

<76> As proven in Examples of the present invention (refer to Examples 5, 6 and 7), the present inventors discovered first that LlCAM is expressed in cholangiocarcinomacells to the extent of overexpression in about 40% of cholangiocarcinoma patients. It was also first revealed by the present inventors that LlCAM is a poor prognostic factor which plays an important role in the tumor progression of cholangiocarcinoma cells to thus increase the risk of death, and that EGFR, previously known to be a poor prognostic factor for cancer, is not a poor indicator for cholangiocarcinoma. Thus, inhibitors against the activity or expression of LlCAM in accordance with the present invention can be specifically applied to the diagnosis and treatment of LiCAM-expressed cancers, especially, cholangiocarcinoma.

<77> Besides, immunohistochemical staining assays showed that LiCAM is expressed at a level below 10% on non-small cell lung carcinoma (NSCLC) cells. When the LlCAM-expressing NSCLC cell lines A549 and NCI-H522 were treated with the A10-A3 antibody, their growth was inhibited in amounts of 14% and 24%, respectively, which fall far short of 40%, the approximate inhibition rate of A10-A3 on the growth of cholangiocarcinoma, demonstrating that the composition of the present invention is therapeutically effective especially for cholangiocarcinoma. This comparison is further described in a Korean Patent Application (entitled, A Pharmaceutical Composition for Treating Cholangiocarcinoma, A Method for Inhibiting Growth or Invasion of Cholangiocarcinomaand a Method for Treating Cholangiocarcinoma), filed on the same date as the present application, the entire contents of which are incorporated herein by reference.

<78> A better understanding of the present invention may be obtained through the following examples, which are set forth to illustrate, but are not to be construed as the limit of the present invention.

<79>

[Mode for Invention] <80> EXAMPLE 1: Culture of cancer cells

<81>

<82> Carcinoma cell lines were cultured using the following media, containing 10% fetal bovine serum (FBS; Gibco) in an incubator at 37°C under 5% CO2. SH-Jl (hepatocellular carcinoma), SCK (cholangiocarcinoma), Choi-CK

(cholangiocarcinoma) and ACHN (Renal cell adenocarcinoma) cells were cultured using MEM medium (Gibco), and SK-0V3 (ovary adenocarcinoma) cells were cultured using McCoy 5A Medium (Gibco). A549 (non small cell lung carcinoma) cells were cultured in Ham's F12K medium, and NCI-H522 (non small cell lung carcinoma), DMS114 (small cell lung carcinoma), DMS53 (small cell lung carcinoma) and NCI-H69 (small cell lung carcinoma) cells were cultured in RPMI1640 medium. SH-Jl, SCK and Choi-CK cell lines were gifts from Dr. Daegon Kim (Medical School, Chonbuk National University), and other carcinoma cell lines were purchased from ATCC. Normal hepatocytes and HUVEC (human umbilical vein endothelial cells), which all were purchased from Cambrax, were cultured using 10% FBS (Gibco)-containing EGM-2 medium (Hyclone) in an incubator at 37°C under 5% CO₂. Peripheral blood lymphocytes (PBL) were isolated from human blood by Ficoll-gradient centrifugation.

<83> <84> EXAMPLE 2: Preparation of A10-A3 monoclonal antibody binding to cancer cells Choi-CK and SCK

<85>

<86> The cultured Choi-CK and SCK carcinoma cells were detached using cell dissociation buffer (Invitrogen), and 5 X 10 cells were suspended in 30 μi of

PBS. Balb/c mice were injected with Choi-CK cells in the right foot pad, and with SCK cells in the left foot pad 3 days later. Mice were then boosted six times at 3-4 day intervals, and were finally immunized one day before cell fusion. The culture of FO myeloma cells (ATCC, USA), to be fused with lymph node cells, was commenced in 10% FBS-containing DMEM (Gibco) two weeks before cell fusion. Popliteal lymph nodes were removed from the mice immunized with Choi-CK and SCK cells, washed well with DMEM medium (Gibco) and finely teased. The cell suspension was transferred into a 15-m# tube. FO myeloma cells were harvested by centrifugation, suspended in 10 ml of DMEM medium,

6 and counted along with the lymph node cells. Then, 10 FO myeloma cells and

10 lymph node cells were mixed in a 50-m£ tube and centrifuged at 200 x g for

5 min. After the supernatant was discarded, the tube was incubated for 2 min in a beaker containing water at 37°C. After the tube was tapped to loosen the cell pellet, 1 ml of PEG (Gibco) was slowly added over one minute to the tube while the tube was gently shaken in a water bath at 37^°C . After the cells were centrifuged at 100 x g for 2 min, 5 ml of DMEM medium was slowly added over 3 min to the tube, and 5 ml of DMEM medium wasfurther added slowly over 2 min. The cells were then harvested by centrifugation at 200 x g. In order to increase cell fusion efficiency and cell viability, the basal medium (DMEM + 20% FBS) was supplemented in advance with 10% Hybridoma Cloning Factor (BioVeris, USA). The recovered cells were carefully suspended in 30 ml of the normal medium (DMEM + 20% FBS) supplemented with Hybridoma Cloning Factor. After the cell suspension was incubated in a CO₂ incubator at 37°C

for 30 min, 10 cells (70 μi) were aliquotted into a 96-well plate and incubated in a CO2 incubator at 37^°C. The next day, 70 μl of HAT medium was added to each well, and the plate was observed for whether colonies were formed in HAT medium at 3-day intervals for a period of over 2 weeks. The culture supernatantsof hybridoma colonies, obtained by fusing lymphocytes, isolated from lymph nodes from mice immunized with Choi-CK cells and from lymph nodes from mice immunized with SCK cells, with myeloma cells, were used in the following tests.

<87> Clones expressing antibodies were selected using sandwich ELISA (Enzyme Linked Immunosorbent Assay). 100 μi of the hybridoma culture was added to a plate coated with 2 μg/yύ of anti-mouse IgG or IgM antibody and allowed to react at 37°C for 1 hr. The plate was then incubated for 1 hr in a 1:5,000 dilution of horseradish peroxidase (HRP; Sigma)-conjugated anti-mouse IgG or IgM antibody. After the plate was washed with 0.08% Tween 20-containing phosphate buffer, a substrate solution containing OPD (Sigma) and H2O2 was added to each well, and absorbance was measured at 492 run using a spectrophotometer in order to select clones producing antibodies.

<88> Among the selected clones, the culture supernatants of hybridomas that secreted a monoclonal antibody relatively stably were tested for binding capacity to SCK and Choi-CK cells. In detail, the cultured Choi-CK cells were treated with cell dissociation buffer (Gibco) for 20 min at 37^°C to be dissociated into single cells, and were passed through a 40- μm strainer. 5

5 X 10 cells were used in flow cytometry,, The SCK and Choi-CK cells, dissociated into single cells, were suspended in PBA (1% BSA in PBS), and antibody supernatants were allowed to react at 4°C for 30 min. After the cells were centrifuged at 1200 rpm for 5 min, 100 μi of the supernatant was discarded, and the cells were allowed to react with a 1:200 dilution of anti- mouse Ig-FITC (BD) at 4°C for 30 min. After the cells were washed with PBA twice, propidium iodide (PΙ)-negative cells were selected and evaluated for binding capacity to SCK and Choi-CK cells using a FACS caliber. <89> Various hybridomas secreting antibodies binding to SCK and Choi-CK cells were selected, stabilized through continuous subculture, and then subcloned. A hybridoma secreting an antibody, A10-A3, stably maintaining the specificity to SCK and Choi-CK cells through subcloning, was selected. <90> The hybridoma secreting the A10-A3 antibody was designated "hybridoma A10-A3". The hybridoma was deposited at KCTC (Korean Collection for Type Cultures; Korean Research Institute of Bioscience and Biotechnology (KRIBB), 52, Oun-dong, Yusong-ku, Taejon, Korea)) on Feb. 20, 2006 and assigned accession number KCTC10909BP.

<91>

<92> EXAMPLE 3: Evaluation of cell surface expression of LlCAM in lung carcinoma cell lines

<93>

<94> The hybridoma A10-A3 cell line was cultured in a serum-free medium (PFHM, Invitrogen), and the secreted A10-A3 antibody was purified using a protein G-Sepharose column (Pharmacia, Sweden) (Fike et al . , Focus 12: 79, 1990). The purified A10-A3 antibody was evaluated for binding capacity for cholangiocarcinoma cells using fluorescent staining according to the same method as in Example 3(FIG. 1). In FIG. 1, empty peaks outlined with solid lines represent samples treated with the monoclonal antibodies A10-A3 and 4- 63 and the known anti-LICAM antibodies 5G3 (Pharmingen, San Diego, USA) and UJ127 (Chemicon), while the filled peak is background fluorescence in the presence of the secondary antibody alone. The binding capacity of A10-A3, 4- 63, 5G3 and UJ127 antibodies for various carcinoma cells was analyzed using FACS caliber. FACS analysis revealed that the monoclonal antibodies bind to NCI-H522, A549, DMSl14, DMS53 and NCI-H69 lung carcinoma cells (panels A, B, C and D, FIG. 1), while they do not bind to ACHN carcinoma cells, normal cells, hepatocytes, HUVEC or peripheral blood lymphocytes (PBL).

<95>

<96> EXAMPLE 4: Isolation and identification of antigen recognized by the monoclonal antibody A10-A3

<97> <98> EXAMPLE 4-1: Antigen isolation

<99>

<ioo> A cell surface protein recognized by the monoclonal antibody A10-A3 was isolated as follows. First, Choi-CK cells were washed with PBS and biotinylated with EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL). The cells were incubated in lysis buffer (25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 2 βg/ml aprotinin, 100 μg/mi phenylmethylsulfonyl fluoride, 5 μg/mit leupeptin) at 4°C for 20 min. After the cells were centrifuged to remove cell debris, the supernatant was recovered, and protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Pierce).

<ioi> The cell lysate was allowed to react with 20 βi of protein G plus- sepharose (Santa Cruz Biotechnology, Santa Cruz) at 4°C for 2 hrs, and was centrifuged to remove proteins non-specifically binding to protein G plus- sepharose. The supernatant was recovered and allowed to react with about 1 βg of antibody at 4^°C for 12 hrs. Twenty βi of protein G plus-sepharose was added to the reaction mixture, followed by incubation at 4°C for 2 hrs. The reaction mixture was centrifuged, and the precipitate was recovered. The recovered precipitate was washed with cell lysis buffer more than ten times, and the remaining proteins were separated using 10% SDS-PAGE.

<iO2> The proteins were transferred onto a nitrocellulose membrane and subjected to Western blotting. The nitrocellulose membrane was blocked with 5% skim milk-containing PBST (PBS + 0.1% Tween 20) for 1 hr, and washed with PBST more than twice. The blot was then incubated for 1 hr with Streptavidin-horseradish peroxidase (HRP) conjugate (1:1,500; Amersham Biosciences). After the blotwas washed with PBST five times, biotinylated proteins were developed with an ECL reagent (Amersham Biosciences).

<i03> The A10-A3 antibody was found to bind to a protein of about 200 kDa (panel A, FIG. 2). In order to collect a protein immunoprecipitated by the

8

A10-A3 antibody, cell lysates from 1 X 10 Choi-CK cells were subjected to immunoprecipitation according to the same method as described above, and electrophoresed on a SDS-PAGE gel. The gel was stained with Coomassie G250 (Biorad).

<104>

<iO5> EXAMPLE 4-2: Antigen identification using mass spectrometry

<106>

<iO7> The SDS gel containing a protein immunoprecipitated by the A10-A3 antibody was stained with Coomassie G250 (BIO-RAD). A protein band was excised from the gel, washed with 30% methanol for 5 min, and finely cut. The gel pieces were dehydrated in 100% acetonitrile for 10 min, and completely dried in a vacuum centrifuge for 30 min. The dried gel pieces were incubated with 300 ng of trypsin (Promega) in 50 mM ammonium bicarbonate for 16 hrs at 37°C . The digested peptides were extracted with 100 μi of 50 mM ammonium bicarbonate three times, and dried in the vacuum centrifuge. The peptide mixture was analyzed using electrospray quadrupole time-of-flight tandem mass spectrometry (ESI Q-TOF MS/MS) (Q-TOF micro, MicroMass). The protein recognized by the A10-A3 antibody was identified as the Ll Cell Adhesion molecule (LlCAM) (FIG. 3). In FIG. 3, the underlined region represents the amino acid sequence actually identified by Q-TOF. Thus, as described in Example 3-1, a biotin-labeled Choi-CK cell lysate was immunoprecipitated with the anti-LlCAM monoclonal antibody JU127.11, purchased from Chemicon (USA), and the blot was developed with ECL. As shown in panel A of FIG. 2, the A10-A3 antibody and the anti-LlCAM antibody were found to immunoprecipitate a protein at the same molecular size of about 200 kDa.

<108>

<i09> EXAMPLE 4-3: Identification of LlCAM antigen using Western blotting

<110>

<πi> In order to confirm that the A10-A3 antibody recognizes LlCAM, immunoprecipitation was carried out in a Choi~CK cell lysate using the A10-A3 antibody.

<ii2> The cell lysate was allowed to react with 20 μi of protein G plus- sepharose (Santa Cruz Biotechnology, Santa Cruz) at 4°C for 2 hrs, and centrifuged to remove proteins non-specifically binding to protein G plus- sepharose. The supernatant was recovered and allowed to react with about 1 μg of antibody at 4°C for 12 hrs. Twenty μS of protein G plus-sepharose was added to the reaction mixture, followed by incubation at 4⁰C for 2 hrs. The reaction mixture was centrifuged, and the precipitate was recovered (preclearing of FIG. 2). The recovered precipitate waswashed with cell lysis buffer more than ten times, and remaining proteins were separated on 10% SDS- PAGE without mercaptoethanol .

<ii3> The proteins were transferred onto a nitrocellulose membrane and subjected to Western blotting. The nitrocellulose membranewas blocked with 5% skim milk-containing PBST (PBS + 0.1% Tween 20) for 1 hr, and washed with PBST more than twice. The blot was then incubated for 1 hr in the known anti-LICAM antibody UJ127 (Chemicon) as the primary antibody. After being washed with PBST five times, the blot was incubated for 1 hr with anti-mouse IgG-HRP conjugate (1:1,500; Sigma). After the blot was washed with PBST five times, biotinylated proteins were developed with an ECL reagent (Amersham biosciences) . The anti-LICAM antibody was found to bind to a protein of about 200 kDa, which was immunoprecipitated with the A10-A3 antibody (panel B, FIG.2). This result confirmed that the A10-A3 antibody recognizes LlCAM.

<114>

<ii5> EXAMPLE 4-4: Expression of soluble LlCAM

<116>

<ii7> In order to construct an expression vector for expressing soluble LlCAM, total RNA was isolated from Choi-CK carcinoma cells using an RNA extraction kit (Roche co.). Using an RT-PCR kit (Roche Co.), PCR was carried out using the isolated total RNA as a template, two terminal primers Ig-dom-F (5'-GAG GAG GAA TTC CGG CGC CGG GAA AGA TGG TCG TGG CG-3¹ , 38 mer) and Ll-Fn- Stop-R (5'-CTC TAG AGT TCT CGA GTC AGA GCC TCA CGC GGC C-3¹ , 34 mer), and pfu polymerase (Solgent Co.). PCR conditions included preincubation at 95°C for 5 min, 25 cycles of 30 sec at 95°C , 30 sec at 58^°C and 2 min at 72°C, and finally elongation for 10 min at 72°C .

<ii8> The amplified soluble Ll DNA fragment was digested with EcoR I and Xho I and electrophoresed on a 1% agarose gel. The Ll DNA fragment was excised from the gel and purified with a gel purification kit (Intron co.). The digested Ll DNA fragment was ligated with a pJK-dhfr2 expression vector (Aprogen), digested with EcoR I and Xho I using T4 DNA ligase (Roche co.) at 16°C for 30 min, and transformed into E. coli DH5α by heat shock. Plasmid DNA was isolated from the transformed cells, and the DNA sequence thereof was determined. DNA sequencing revealed that cDNA of soluble LlCAM was successfully cloned. The expression vector thus obtained was designated "pJK-dhfr2-Ll-monomer\

<ii9> pJK-dhfr2-Ll-monomer DNA was transfected into HEK293T cells (ATCC CRL11268, hereinafter referred to as 293T) in order to express soluble LlCAM in the monomer form.

<12O> Ten μg of the expression vector DNA and Lipofectamine 2000 (Invitrogen co.) were added individually to 500 μi of Opti-MEM medium (Gibco BRL), and were allowed to stand at room temperature for 5 min. Then, the vector DNA was mixed with lipofectamine, and the mixture was allowed to react at room temperature for 15 min. During the formation of DNA-I ipofectamine complexes, 293T cells were carefully washed with PBS (pH 7.4), and Opti-MEM medium was carefully added to the cells and was then removed. The DNA-I ipofectamine complexes were mixed with 4 ml of Opti-MEM medium, and carefully dropped over the cells. The cells were incubated in an incubator at 37^°C. After 6 hrs, the cells were re-fed with 5 vat of Opti-MEM medium, and further cultured for 3 days.

<121>

<i22> EXAMPLE 4-5: Evaluation of binding specificity of antibodies to soluble LlCAM

<123>

<124> A culture fluid of 293T cells expressing soluble LlCAM and another culture fluid of 293T cells not expressing soluble LlCAM were subjected to 10% SDS-PAGE and then to Western blotting. The nitrocellulose membrane was blocked with 5% skim milk-containing TBST (TBS + 0.05% Tween 20) at 4°C for 12 hrs, and washed with TBST more than twice. The blot was then incubated for 1 hr with primary antibodies, the known anti-LICAM antibodies UJ127 (Chemicon) and 5G3 (Pharmingen), and the A10-A3 and 4-63 antibodies, each antibody diluted 1:10,000 in 5% skim milk-containing TBST. After being washed with TBST five times, the blot was incubated for 1 hr with anti-mouse IgG-HRP conjugate (1:5000; Sigma). The blot was washed with PBST five times and developed with an ECL reagent (Amersham biosciences). Each antibody was found to bind to soluble LlCAM of about 200 kDa (panel C, FIG. 2). Also, ELISA for the Ll-expressed cell culture using the above antibodies revealed that each antibody has binding specificity for the expressed soluble LlCAM.

<125>

<i26> EXAMPLE 5: Immunohistochemical staining of Cholangiocarcinoma tissue

<127>

<128> Sections 3 μm thick were prepared from tumors for the immunohistochemical staining of cholangiocarcinoma tissues. The sections were placed on a slide coated with poly-L-lysine and dried at 60^°C for 3 hrs. The sections were then deparaffinized in xylene at room temperature for 5 min three times, and hydrated in 100%, 90%, 80% and then 70% alcohol for 1 min each. The slide was dipped in a target retrieval solution (DAKO, Carpinteria, CA) to recover antigenicity, and was washed with TBST (Tris- buffered saline-Tween 20), which was pre-boiled for 4 min using a pressure cooker. A biotin-free Tyramide Signal Amplification System, CSA II (DAKO, Carpinteria, CA) was used for highly sensitive detection for immunohistochemical staining. The slide was incubated in 3% hydrogen peroxide for 5 min to block the non-specific binding of antibodies. After being washed with TBST twice for 5 min each time, the sections were incubated in sufficient serum-free protein block for 5 min to block the non-specific binding of proteins. The tissue sections were incubated with primary antibodies (A10-A3 and 4-63, 1:50 dilution) for 15 min, and then with anti- mouse immunoglobulin-HRP for 15 min. The sections were then incubated with an amplification reagent and anti-fluorescetn-HRP for 15 min each. Finally, the sections were staiαed with DAB for 5 min and counter-stained with Meyer's hematoxylin, followed by TBST washing for 5 min twice. A negative control was stained according to the same procedure as described above, except that normal sheep serum not containing the primary antibody, or normal mouse IgGl serum, was used in place of the primary antibody. Neither of the A10-A3 or 4-63 antibodies were found to bind to normal tissues, but they were observed to bind to cholangiocarcinoma tissues (FIG. 4).

<i29> This result accounts for the expression of LlCAM in cholangiocarcinoma tissues.

<130>

<i3i> LlCAM expression was observed in 45.2% of 42 intrahepatic cholangiocarcinoma patients and 39.8% of 103 extrahepatic cholangiocarcinoma patients, as analyzed by immunohistochemical staining using the A10-A3 antibody (FIG. 5). Particularly, LlCAM is expressed at a high level in the invasive front, which explains the metastasis initiation of cholangiocarcinoma (FIG.4).

<132>

<i33> EXAMPLE 6: Statistical analysis for the expression rate of LlCAM in Cholangiocarcinoma and the survival rate of Cholangiocarcinoma patients

<134>

<i35> The correlation between LlCAM expression rate and survival rate was analyzed in patients suffering from extrahepatic cholangiocarcinoma (60 cases). Patient groups showing high LlCAM' expression rates were found to decrease with statistical significance in overall survival (OS) and disease free survival (DFS), that is, to increase in death risk, compared to those with low LlCAM expression rates (FIG. 6). As seen in the survival graph, there are great differences and statistical significance in 2-year OS between cholangiocarcinoma patients exhibiting high and low LlCAM expression rates. Also, the 2-year DFS of cholangiocarcinoma patients with low LlCAM expression rates was different with statistical significance from that of cholangiocarcinoma patients with high LlCAM expression rates.

<136> In contrast, there is no statistical significance in the correlation between the survival of patients and the expression rate of EGFR (epidermal growth factor receptor), known to be overexpressed in cholangiocarcinoma or other tumors (FIG. 6). These results imply that antibodies to LlCAM are useful for the diagnosis and treatment of cholangiocarcinoma and can be applied to the early diagnosis of the metastasis of cholangiocarcinoma, thereby increasing the therapeutic effect thereof on the disease. It is apparent from the data of the statistical analysis for correlation between LlCAM expression rate and survival that higher mortality occurs in cholangiocarcinoma patients with high LlCAM expression rates than those with low LlCAM expression rates.

<137>

<138> Demonstrating that LlCAM is a poor prognostic factor, the results indicate that LlCAM may be a target for the treatment of cholangiocarcinoma. Although expressed at a high level in cholangiocarcinoma, in contrast, EGFR, which had been used as a target of therapeutic agents for current clinical use in the treatment of colon cancer (e.g., cetuximab, chimeric antibody to EGFR), was proven not to be a poor prognostic factor for cholangiocarcinoma, as deduced from the correlation between EGFR expression rates and survival rates. This is proof that not all of the molecules which are overexpressed in cancer arepoor prognostic factors for cancer and thus important targets for the treatment thereof.

<139>

<i40> EXAMPLE T- Effect of the suppression of LlCAM expression on Cholangiocarcinoma cells

<141>

<i42> EXAMPLE 7-1: Inhibition of LlCAM expression in cholangiocarcinoma cells using siRNAs

<143>

<i44> LlCAM expression was knocked down in Choi-CK and SCK cells. To this end, the carcinoma cells were transfected with two siRNA oligonucleotides for LlCAM (5'-TGGTACAGTCTGGGdtdt-3' and 5'-CAGCMCTTTGCTCAGAGGdtdt-3' ) or a nonspecific oligonucleotide (5'-CAGTCGCGTTTGCGACTGGdtdt-3' , and cultured for 72 hrs. LlCAM knockdown was estimated by flow cytometry, RT-PCR and Western blotting using the A10-A3 antibody. As a result, compared to a control treated with the non-specific siRNA, Choi-CK and SCK cells treated with siRNAs were measured to decrease in the total expression of LlCAM and in cell surface LlCAM level (panel A, FIG. 7).

<145>

<i46> EXAMPLE 7-2: Evaluation of activity of cholangiocarcinoma cells after treatment with siRNA against LlCAM

<147>

<i48> Cell proliferation, invasion and migration were compared between cholangiocarcinoma cells transfected with the siRNA against LlCAM and with the non-specific siRNA. The degree of proliferation was estimated by counting the number of cells with the aid of Tryphan Blue 72 hours after culturing the same number of cells. The degrees of invasion and migration were analyzed using a QCM 24-well cell invasion assay kit (Chemicon) and a QCM 24-well colorimetric cell migration assay kit (Chemicon), respectively. Carcinoma cells, in which LlCAM was knocked down by siRNA, displayed a decreased degree of proliferation, invasion and migration compared to carcinoma cells expressing LlCAM at normal levels. These results indicate that LlCAM plays a role in the growth, migration and invasion of cholangiocarcinoma cells (panel B, FIG. 7).

<149>

<i50> EXAMPLE 8: Inhibition of LlCAM-specific antibody against growth of Cholangiocarcinoma cells

<151>

<152> Anti-LICAM antibodies were evaluated for their inhibitory effects on the growth of cholangiocarcinoma cells. Choi-CK and SCK cells, to which the A10-A3 antibody binds, were used in this test while an ovarian carcinoma cell line (SK-OV-3) and ACNH served as a positive control and a negative control, respectively. These cells were seeded at a density of 2 X 10 cells/well in

24-well plates containing 3 ml of a medium per well, and cultured. The monoclonal antibody was added to each well at a concentration of 10 μg/ml before the cells were incubated in an incubator at 37°C for 10 days. After being collected, the cells, alive and dead, were counted using 0.2% Tryphan Blue and the survival rates of the cells were expressed as percentages of total cell number. When treated with the A10-A3 antibody, Choi-CK and SCK cells grew at a distinctively decreased rate, like SK-0V3 cells, but ACHN cells proliferated normally (panel A, FIG. 8). On the other hand, 4-63 antibody was found to inhibit the growth of cholangiocarcinoma cells (panel B, FIG.8).

<i53> Upon the treatment of cholangiocarcinoma cells therewith, UJ127 (Chemicon) antibody, known to specifically bind to LlCAM, inhibited the growth of the cancer cells significantly. In the case of 5G3 (Pharmingen), which also specifically binds to LlCAM, however, the growth of the cholangiocarcinoma cell (Choi-CK) was inhibited only slightly (panel C, FIG. 8). The 5G3 antibody was found to bind to the Choi-SK cell (panel C, FIG. 1). These results indicate that the binding of anti-LlCAM antibodies to tumor cells does not always inhibit the growth of tumor cells.

<154>

<i55> EXAMPLE 9: Inhibitory effects of LlCAM-specific antibodies on invasion and migration of Cholangiocarcinoma cells

<156>

<i57> A cell invasion assay was carried out using a QCM 24-well cell invasion assay kit (CHEMICON). The ECM layer of each insert was rehydrated with 300 μl of pre-warmed serum-free media (RPMI, 10 mM HEPES, pH 7.4) at room temperature for 30 min. Choi-CK, SCK, SK-0V3, and ACHN cells were washed twice with PBS and treated with 3 mi of trypsin-EDTA in an incubator at 37°C.

5

The detached cells were harvested and adjusted to a density of 1 X 10 cells in 200 jd of invasion medium (RPMI, 10 mM HEPES, pH 7.4, 0.5% BSA). The cells were then inserted into each insert and incubated with the A10-A3 antibody, 4-63 antibody, 5G3 antibody (10 μg/mt) and normal mouse IgG (10 μg/ \\\l) . The lower chamber was filled with an invasion medium supplemented with 10% FBS, and incubated in an incubator at 37⁰C for 72 hrs. Afterwards, the cells and medium remaining in each insert were removed, and each insert was transferred to a new well. Each insert was placed in 225 μl of pre-warmed cell detachment solution, and incubated in an incubator at 37°C for 30 min. The insert was shaken to completely detach the remaining cells, and 75 μl of lysis buffer/dye solution was added to each well containing cells and the cell detachment solution, followed by incubation at room temperature for 15 min. 200 μl of the mixture was transferred to a 96-well plate, and fluorescence was read at 480/520 nm. The A10-A3 antibody was found to inhibit the cell invasion of Choi-SK, SCK and SK.-0V3, but not to induce inhibition of the cell invasion (panel A, FIG. 9). Also, the 4-63 antibody reduced the invasion of Choi-SK cells (panel A, FIG. 9). The 5G3 antibody inhibited the invasion of Choi-SK cells less efficiently than did the A10-A3 and 4-63 antibodies (panel A, FIG. 7).

<158> A cell migration assay was conducted in the same procedure as described above, with the exception that collagen type I was layered at a concentration of 10 g/m£ on the bottom of the insert. The A10-A3 antibody was observed to inhibit the cell migration of Choi-SK, SCK and SK-OV-3, but not to inhibit the cell migration of ACHN (FIG. 9). Also, the antibodies inhibited the migration of Choi-SK, SCK and SK-OV-3 (FIG. 9).

<159>

<i60> EXAMPLE 10: Inhibitory effect of A10-A3 antibody on signal transduction in Cancer cells

<161>

<i62> EXAMPLE 10-1: Inhibition of A10-A3 antibody against the PCNA expression of cancer cell

<163> <i64> Western blotting was performed to examine whether the proliferating cell nuclear antigen (PCNA) expression, accounting for cell proliferation, was inhibited by the A10-A3 antibody. In this regard, Choi-SK cells were incubated for 72 hours with A10-A3 or IgG 10, collected, and dissolved in a cell lysis buffer. Protein concentration was determined using a BCA (bicinchoninic acid) protein assay kit (Pierce). 40 μg of the protein was run on 8% SDS-PAGE and transferred onto a nitrocellulose membrane at 25 V for 90 min. The blots were blocked overnight at 4°C in 5% skim milk and incubated for 1 hour with mouse monoclonal anti-PCNA (Novocastra Laboratories 1:500) antibody and anti-β actin (Oncogene, 1:4000) antibody. Then, the membrane was treated with anti-mouse horseradish peroxidase-conjugated antibody (Cell Signaling, 1:1000) and washed with PBST before visualizing PCNA and β -actin with an enhanced chemi luminescence reagent (ECL) (Amersham Pharmacia Biotech). Significantly reduced expression of PCNA was observed only in the Choi-SK cells treated with the A10-A3 antibody.

<165>

<i66> EXAMPLE 10-2: Inhibition of PCNA expression ERK phosphorylation

<167>

<168> Western blotting was performed to determine whether the A10-A3 antibody decreases mitogen-activated protein kinase (MAPK), which is involved in the growth, migration and survival of tumor cells. Choi-SK cells were incubated with 10 μg/mi of A10-A3 antibody or mouse IgG for 72 hours, harvested, and lysed with cell lysis buffer. Protein concentrations were determined using a bicinchoninic acid (BCA) protein assay kit (Pierce), and 40 μg of proteins were run on 12% SDS-PAGE. The proteins were transferred onto a nitrocellulose membrane at 25 V for 90 min. The blots were blocked with 5% skim milk at 4^°C overnight, and incubated overnight with rabbit polyclonal anti-phospho MAPK antibody (Ab cam, diluted 1:1000) in 1% skim milk. The same amount of proteins was treated according to the same procedure described above in order to investigate the expression of non-phosphorylated MAPK, and the blocked nitrocellulose membrane was incubated with anti-MAPK antibody (Ab cam, diluted 1:1000) for 1 hr. The blots were incubated with anti-rabbit HRP-conjugated antibody (Cell Signaling, diluted 1:10000) for 1 hr. After the blots were washed with PBST, phospho-MAPK and MAPK were detected using ECL (Amersham Pharmacia Biotech). Among the Choi-CK cells expressing the same MAPK, only those treated with the A10-A3 antibody remarkably decreased in phospho-MAPK level (FIG. 10A).

<169>

<i70> EXAMPLE 10-3: Inhibition of AKT phosphorylation by A10-A3 antibody

<171>

<172> Western blotting was performed in order to determine whether the A10-A3 antibody decreases AKT phosphorylation, which is involved in the survival of tumor cells. Choi-CK cells were incubated with 10 μg/m£ of A10-A3 or mouse IgG for 1, 1.5 and 2 hours, harvested and lysed with cell lysis buffer. Protein concentrations were determined using a BCA protein assay kit (Pierce), and 40 μg of the proteins were run on 12% SDS-PAGE. The proteins were transferred onto a nitrocellulose membrane at 25 V for 90 min. The blots thus formed were blocked with 5% skim milk at 4°C overnight, and incubated overnight with rabbit polyclonal anti-phospho Akt antibody (Ab cam, 1:1000 diluted) and rabbit polyclonal anti-Akt (Abeam, 1:1000 diluted) in 1% skim milk, followed by reaction with anti-rabbit IgG HRP (Santa Cruz 1:1000 diluted) for 1 hour. After the blots were washed with PBST, phospho-Akt and total Akt were detected using ECL (Amersham Pharmacia Biotech). Phospho-Akt levels remarkably decreased only in A10-A3 antibody-treated Choi-CK cells (FIG. 10B).

<173>

<i74> EXAMPLE 10-4: Inhibition of FAK activation by A10-A3 antibody

<175>

<i76> Western blotting was performed to determine whether the A10-A3 antibody decreases focal adhesion kinase (FAK) phosphorylation, which plays an important role in the growth and migration of tumor cells. Choi-CK and SCK cells were incubated with 10 μg/xΑl of A10-A3 antibody for 0.5, 1, 1.5 and 2 hours, harvested and lysed with cell lysis buffer. Protein concentrations were determined using a BCA protein assay kit (Pierce), and 40 μg of proteins were run on 7.5% SDS-PAGE. The proteins were transferred onto a nitrocellulose membrane at 25 V for 90 min. The blots thus formed were blocked with 5% skim milk at 4°C overnight, and incubated overnight with rabbit polyclonal anti-phospho FAK antibody (Ab cam, 1:1000 diluted) in 1% skim milk and then with anti-β-actin (Oncogene, 1:4000 diluted) for 1 hr. The blotswere then incubated with anti-rabbit HRP-conjugated antibody (Cell Spring, 1:10000 diluted) for 1 hr. After the blot was washed with TBST, phospho-FAK and β-actin levels were detected using enhanced chemi luminescence reagent (ECL) (Amersham Pharmacia Biotech). Both of the Choi-CK and SCK cells treated with the A10-A3 antibody were observed to decrease in phospho-FAK level (FIG. 10C).

<177>

<i78> EXAMPLE 11: Assay of A10-A3 antibody for inhibitory activity against cancer cells in mouse model

<179>

<i80> Nude mice Balb/c nu/nu which were 6-8 weeks old and weighed 18-22 g were purchased via Central Lab. Animal Inc. from Japan SLC and acclimated for one week in a lab of the Korean Research Institute of Bioscience and

Biotechnology. Choi-CK cells (3x10) were subcutaneousIy transplanted into

3 the mice and were grown to a tumor mass having a size of 390 mm on Day 20

(FIG. 10A). The tumor volume was assessed according to the formula V=long axis (mm) x short axis mm) x height (mm) x l/2.0n the final day, the mice were sacrificed with C0₂gas and the tumors were separated and weighed. The body weights of the mice were also measured to determine toxicity. Standard deviations (SDs) and p values were evaluated using ANOVA (Prism, GraphPad Software, USA) and students t-test.

<181>

<i82> When the A10-A3 ant ibody was injected at a dose of 10 mg/kg into a tai l vein three times a week from day 1, potent anticancer effects were observed until Day 20 (panel A, FIG. 1). Mouse IgG antibody was injected at the same

3 dose as a control. The standard tumor volume was measured to be 232 mm , which accounted for the anticancer activity about 40% higher than the control (FIG. HA). On the final day (Day 20), the tumors were separated and weighed (Panel B, FIG. 11). The standard tumor weights of the control and the AlO- A3-administered group were 872 mg and 516 rag, respectively, which accounted for the fact that the anticancer activity of the A10-A3 antibody was 40% higher than that of the control.

<183> The nude mice were monitored for body weight for 20 days in order to predict the toxicity of A10-A3. Also, the behavior of the mice was observed with the naked eye (panel D, FIG. 11). Compared to the control on Day 20, the mice treated with the antibody of interest were observed to undergo neither body weight changes nor abnormal behaviors.

<184>

[Industrial Applicability]

<185> As described hitherto, it is first discovered in the present invention that LlCAM is expressed on the cell surface of cholangiocarcinoma to play an important role in the growth and invasion of cancer and is a poor prognostic factor for cholangiocarcinoma. Therefore, antibodies, binding to the LlCAM protein on the cholangiocarcinoma cell surface or siRNAs, antisense oligonucleotides or shRNAs, suppressing LlCAM expression in cholangiocarcinoma cells, and a pharmaceutical composition comprising the same according to the present invention can be applied to the treatment of cholangiocarcinoma because they are proven to inhibit the growth, invasion and migration of cholangiocarcinoma.

<186>

Claims

[CLAIMS]

[Claim 1]

<188> A pharmaceutical composition for inhibiting growth or metastasis of cholangiocarcinoma, comprising a LlCAM activity or expression inhibitor, said LlCAM activity inhibitor being selected from among an anti-LlCAM antibody inhibiting LlCAM activity, antigen binding fragments of the anti-LICAM antibody, variants of the anti-LICAM antibody, and variants of the antigen binding fragments of the anti-LICAM antibody, said LlCAM expression inhibitor being an oligonucleotide suppressing LlCAM expression.

<189>

[Claim 2]

<19O> The pharmaceutical composition according to claim 1, wherein the LlCAM activity inhibitor recognizes a membrane-bound form or a soluble form of the

LlCAM.

<191>

[Claim 3]

<i92> The pharmaceutical composition according to claim 1, wherein the oligonucleotide suppressing LlCAM expression is selected from a group consisting of an antisense oligonucleotide, an siRNA and an shRNA against a gene encoding LlCAM.

<193>

[Claim 4]

<194> The pharmaceutical composition according to claim 1, wherein the antibody is 4-63, secreted by a hybridoma having accession number KCTC 10966BP, or UJ127.

<195>

[Claim 5]

<i96> The pharmaceutical composition according to claim 3, wherein the siRNA has a sequence of 5'-TGGTACAGTCTGGGdtdt-3' or 5'-CAGCAACTTTGCTCAGAGGdtdt-3'

<197>

[Claim 6] <198> A method of treating cholangiocarcinoma, comprising administering the composition of claim 1.

<199>

[Claim 7]

<2oo> A method of inhibiting growth or metastasis of cholangiocarcinoma by inhibiting activity of LlCAM or suppressing the expression of LlCAM.

<201>

[Claim 8]

<202> A method of diagnosing cholangiocarcinoma, using an anti-LlCAM antibody specific for LlCAM.

<203>